Wolfe Research analyst Andy Chen downgraded Akero Therapeutics (AKRO) to Peer Perform from Outperform following Novo Nordisk’s (NVO) plan to acquire Akero for $4.7B upfront, equivalent to about $54 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Akero Therapeutics rises 16.6%
- Midday Fly By: Delta beats, PepsiCo names new CFO
- Akero downgraded to Market Perform from Outperform at LifeSci Capital
- Cautious Hold Rating on Akero Therapeutics Amid Novo Nordisk Acquisition and Regulatory Uncertainties